Fujifilm's CDMO carves foothold in Boston biotech hub with new HQ focused on viral vectors, gene therapies
On the heels of a red-letter year for contract manufacturers, Japan’s Fujifilm has seen its CDMO arm — Fujifilm Diosynth Biotechnologies — earn interest from major Covid-19 vaccine makers for its viral-vector capabilities. Now, the drugmaker is looking to lock down its US footprint in the bustling Boston biotech hub.
Fujifilm will invest roughly $40 million (or 4 billion yen) in a new headquarters in the greater Boston area for its CDMO arm, which will also function as its third viral-vector manufacturing site.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
